Bulk Pharmaceutical API Sources for STROMECTOL

Bulk Pharmaceutical API Sources for STROMECTOL

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		I8898_SIGMA
Molport		MolPort-006-394-715
AvaChem Scientific		71827-03-7
AvaChem Scientific		3002

Bulk Active Pharmaceutical Ingredient (API) Sources for: STROMECTOL

Last updated: August 4, 2025

Introduction

Stromectol, the commercial name for ivermectin, is a widely used antiparasitic agent indicated for the treatment of various parasitic infections, including onchocerciasis, strongyloidiasis, and certain ectoparasitic infestations. The global demand for ivermectin has surged, notably amid initiatives to control onchocerciasis and its emergent applications in other parasitic diseases. An essential component of the pharmaceutical supply chain, the active pharmaceutical ingredient (API) sourcing for ivermectin, requires rigorous quality assurance, regulatory compliance, and supply reliability. This article explores key API suppliers, manufacturing capabilities, and sourcing considerations for ivermectin (Stromectol), providing insights for stakeholders involved in procurement, manufacturing, and healthcare policy.

Ivermectin API: Overview and Market Dynamics

Ivermectin, discovered in the 1970s from Streptomyces avermitilis, is a macrocyclic lactone with potent antiparasitic activity. Its production involves fermentation processes, and the API must conform to stringent pharmacopeial standards, such as USP, EP, or JP. The API market is characterized by a limited number of manufacturers due to the specialized fermentation technology, regulatory hurdles, and quality management systems needed.

Global demand for ivermectin has increased substantially, driven by endemic parasitic diseases and recent utilization in emerging indications like COVID-19. This has heightened the importance of reliable API sourcing to prevent supply disruptions, ensure product quality, and meet market demands.

Leading API Suppliers for Ivermectin (Stromectol)

1. Merck KGaA (Germany)

Overview: Merck, the original patent holder for ivermectin, continues to manufacture and supply the API through its generics division. Its production facilities adhere to this pharmaceutical giant's rigorous quality standards and Good Manufacturing Practices (GMP).

Strengths:

• Proven quality control.
• Long-standing market presence.
• Extensive regulatory compliance infrastructure.

Limitations:

• Supply restrictions owing to Merck’s strategic policies; often serves primarily its brand products.
• Less accessible to small- and medium-sized enterprises.

2. M/S Croda International Plc (UK)

Overview: Croda is known for its specialty chemicals, but it also supplies pharmaceutical-grade intermediates and APIs, including ivermectin, primarily for research purposes and niche markets.

Strengths:

• High-quality GMP-certified production.
• Focus on sustainable manufacturing.

Limitations:

• Limited production capacity for large-scale API supply.
• Primarily caters to R&D and niche markets rather than mass commercial distribution.

3. Dongying Tiankang Biotechnology Co., Ltd. (China)

Overview:
Dongying Tiankang is among the increasing number of Chinese manufacturers producing ivermectin API. Their facilities are certified under Chinese GMP standards, with some sites also achieving certifications aligned with WHO GMP.

Strengths:

• Competitive pricing and flexible manufacturing capacity.
• Rapid expansion in API production.
• Ability to serve bulk requirements with shorter lead times.

Limitations:

• Variability in regulatory recognition internationally.
• Concerns related to quality assurance and consistency, requiring thorough qualification audits.

4. Zhejiang Huadong Medicine Co., Ltd. (China)

Overview:
Huadong Medicine supplies ivermectin API with certifications suitable for export to various regulatory regions, including the US and Europe, after compliance with ISO and GMP standards.

Strengths:

• Strong regional reputation.
• Compliant quality management systems.

Limitations:

• Limited global market penetration compared to established Western suppliers.
• Supply volumes may be influenced by regional demand fluctuations.

5. Other Notable Chinese Manufacturers

Additional Chinese firms, such as Zhejiang Haizhou Pharmaceutical Co., Ltd., and Tonghua Dongbao Pharmaceutical Co., Ltd., are emerging API producers, offering competitive pricing and capacity expansions to meet rising global demand.

6. Indian API Manufacturers

India hosts several API producers capable of manufacturing ivermectin, driven by the country’s robust generic pharmaceutical sector.

Key players include:

• Maker’s Laboratories Ltd.: GMP-certified with export licenses.
• Sun Pharmaceutical Industries Ltd.: With strategic alliances and manufacturing facilities dedicated to APIs.

Strengths:

• Cost-effective production.
• Established export routes into regulated markets.

Challenges:

• Quality consistency and regulatory approvals for specific markets.
• Need for rigorous supplier qualification processes.

API Quality and Regulatory Considerations

Procurement of ivermectin API mandates adherence to international quality standards, including GMP certification and compliance with pharmacopeial requirements. Regulatory dossiers and detailed stability data are necessary for API approval and importation, especially in highly regulated markets like the US and EU. Suppliers with US FDA, EMA, or WHO prequalification credentials are preferred for assured quality.

Furthermore, recent supply chain disruptions emphasize the importance of multi-sourcing strategies, fostering resilience against manufacturing setbacks or geopolitical barriers, especially considering geopolitical tensions affecting Chinese or Indian API exports.

Supply Chain and Sourcing Strategies

Given the concentrated nature of ivermectin API production, stakeholders should evaluate integrating multiple suppliers across geographies to mitigate risks. Establishing early engagement with emerging manufacturers, verifying audit reports, and ensuring traceability from fermentation to final API are crucial.

Key considerations include:

• Manufacturing capacity and lead times.
• Regulatory compliance and certifications.
• Pricing and payment terms.
• Quality assurance procedures and batch consistency.
• Supply chain transparency and traceability.

Future Outlook

The market for ivermectin API is anticipated to stabilize and expand, driven by ongoing endemic control programs and new therapeutic indications. Advances in fermentation technology and scalable manufacturing processes are expected to broaden the supplier base, fostering greater competition and supply security.

Regulatory agencies are increasingly emphasizing rigorous quality audits and second-source policies, which influence procurement strategies. Manufacturers investing in technology transfer, capacity expansion, and quality certification will likely maintain a competitive edge.

Key Takeaways

• Limited but Concentrated Supplier Base: The ivermectin API market is dominated by a core group of manufacturers primarily in Europe, China, and India. Diversification reduces risks associated with supply disruptions.

• Regulatory Compliance Critical: Selecting suppliers compliant with GMP, WHO prequalification, and regional regulatory standards ensures global market access and product quality.

• Emerging Chinese Manufacturers: Several Chinese firms are expanding capacities and improving quality standards, offering cost-effective alternatives but warranting thorough qualification.

• Supply Chain Resilience: Multi-source sourcing, early supplier qualification, and transparent supply chain management are essential for maintaining a steady API supply.

• Market Dynamics: Rising demand, new indications, and technological advances will influence future API availability, pricing, and regulatory landscapes.

FAQs

1. What are the primary challenges in sourcing ivermectin API globally?
Supply constraints due to concentrated manufacturing, regulatory approval processes, quality assurance requirements, and geopolitical factors pose significant challenges.

2. Which countries are leading API producers for ivermectin?
China and India dominate as producers, with European companies like Merck maintaining production for original patents and select generics.

3. How do regulatory standards impact API sourcing decisions?
Compliance with GMP, ISO, and regional certifications (FDA, EMA, WHO) determines market eligibility, influences supplier selection, and ensures product quality.

4. What role do emerging Chinese API manufacturers play in the ivermectin supply chain?
They offer increased capacity, competitive pricing, and rapid scalability but require rigorous qualification and quality audits for international distribution.

5. What strategies can companies adopt to secure reliable ivermectin API supplies?
Engage multiple qualified suppliers, establish long-term agreements, verify certifications, monitor quality continuously, and maintain supply chain transparency.

---

References

1. World Health Organization. (2020). Prequalification of Medicines Programme.
2. U.S. Pharmacopeia. (2021). USP General Chapters.
3. European Medicines Agency. (2022). API Manufacturing Standards.
4. Industry Reports. (2022). Global Ivermectin API Market Analysis.
5. D. M. Bannister et al., “Manufacturing and Quality Aspects of Ivermectin API,” Pharmaceutical Technology, vol. 43, no. 8, pp. 26-34, 2019.